COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

Phase II Study of Maintenance Ruxolitinib after Allogeneic Stem Cell Transplantation for Older Patient with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)

Protocol No
DF-HCC-17-273AML-ASCT
Principal Investigator
Sameem Abedin
Phase
II
Summary
Trying to discover if Ruxolitinib will decrease your chances of relapse after having an allogeneic stem cell transplantation.
Description
Ruxolitinib after Allogeneic Stem Cell Transplantation in AML
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category
Hematologic/Blood Related Cancers
ClinicalTrials.gov
go to website